The Expression Characteristics and Function of the RECQ Family in Pan-Cancer

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Aug 26

PMID 37626815

Authors

Yuanyuan Zhou

Xucheng Huang

Liya Wang

Yujia Luo

Affiliations

Soon will be listed here.

Abstract

Background: The genes of the RECQ DNA helicase family play a part in preserving the stability of the genome and controlling different disease mechanisms. However, the expression features of RECQs in relation to pan-cancer, their correlation with the immune microenvironment of tumors, and the landscape of prognostic power are still undisclosed.

Methods: Various sequence and clinical data extracted from 33 cancers were utilized to generate a comprehensive overview of RECQs in the landscape. Afterward, we discovered variations in gene expression, potential enrichment of functions, genetic alterations, and analysis related to the immune response in tumors. Additionally, we explored the clinical characteristics and diagnostic significance of RECQs. And the important association of RECQL4 with liver hepatocellular carcinoma (LIHC) was investigated.

Results: RECQs exhibited extensive mutations in different types of cancers. The expression of RECQ may be influenced by an oncogenic mutation in certain types of cancer, resulting in the observed genomic and epigenetic changes in diverse tumor formations. Furthermore, RECQs originating from tumors exhibited a significant association with the immune microenvironment of the tumor, indicating their potential as promising targets for therapy. Patient prognosis was significantly associated with the majority of genes in the RECQ family. In LIHC, RECQL4 eventually emerged as a separate prognostic determinant.

Conclusions: To summarize, RECQs are essential for the regulation of the immune system in tumors, and RECQL4 serves as a prognostic indicator in LIHC. The results of our study offer fresh perspectives on RECQs from a bioinformatics perspective and emphasize the importance of RECQs in the diagnosis and treatment of cancer.

Citing Articles

Unraveling the mechanisms of RECQL4-mediated cervical cancer progression through the PI3K/AKT pathway.

Huo W, Huang Y, Tian B, Chen X, Lu J, Huang X Transl Oncol. 2024; 50:102146.

PMID: 39378549 PMC: 11491730. DOI: 10.1016/j.tranon.2024.102146.

References

Zhang J, Liu D, Li G, Staveley-OCarroll K, Graff J, Li Z . Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. Sci Adv. 2017; 3(5):e1602133. PMC: 5435412. DOI: 10.1126/sciadv.1602133. View

Tanyi J, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aao5931. View

Hong L, Chen Y, Smith C, Montgomery S, Vincent B, Dotti G . CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30 and CD30 Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions. Cancer Immunol Res. 2018; 6(10):1274-1287. PMC: 7590161. DOI: 10.1158/2326-6066.CIR-18-0065. View

Goldman M, Craft B, Hastie M, Repecka K, McDade F, Kamath A . Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38(6):675-678. PMC: 7386072. DOI: 10.1038/s41587-020-0546-8. View

Jackson S, Bartek J . The DNA-damage response in human biology and disease. Nature. 2009; 461(7267):1071-8. PMC: 2906700. DOI: 10.1038/nature08467. View

Rezazadeh S . RecQ helicases; at the crossroad of genome replication, repair, and recombination. Mol Biol Rep. 2011; 39(4):4527-43. DOI: 10.1007/s11033-011-1243-y. View

Wang G, Cen Y, Wang C, Xiang W, Li S, Ming Y . Elevated RECQL1 expression predicts poor prognosis and associates with tumor immune infiltration in low-grade glioma. Transl Cancer Res. 2022; 11(6):1552-1564. PMC: 9273661. DOI: 10.21037/tcr-21-2762. View

Park J, Riviere I, Gonen M, Wang X, Senechal B, Curran K . Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):449-459. PMC: 6637939. DOI: 10.1056/NEJMoa1709919. View

Bottcher J, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S . NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. 2018; 172(5):1022-1037.e14. PMC: 5847168. DOI: 10.1016/j.cell.2018.01.004. View

10.

Gupta N, Huang T, Nair J, An D, Zurcher G, Lampert E . overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant -mutant ovarian cancer. Sci Transl Med. 2023; 15(701):eadd7872. PMC: 10758289. DOI: 10.1126/scitranslmed.add7872. View

11.

Tang T, Tan X, Wang Z, Wang S, Wang Y, Xu J . Germline Mutations in Patients With Early-Onset Prostate Cancer. Front Oncol. 2022; 12:826778. PMC: 9207501. DOI: 10.3389/fonc.2022.826778. View

12.

Sturm G, Finotello F, Petitprez F, Zhang J, Baumbach J, Fridman W . Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019; 35(14):i436-i445. PMC: 6612828. DOI: 10.1093/bioinformatics/btz363. View

13.

Luchini C, Bibeau F, Ligtenberg M, Singh N, Nottegar A, Bosse T . ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019; 30(8):1232-1243. DOI: 10.1093/annonc/mdz116. View

14.

Larsen N, Hickson I . RecQ Helicases: Conserved Guardians of Genomic Integrity. Adv Exp Med Biol. 2012; 767:161-84. DOI: 10.1007/978-1-4614-5037-5_8. View

15.

Savva C, Sadiq M, Sheikh O, Karim S, Trivedi S, Green A . Werner Syndrome Protein Expression in Breast Cancer. Clin Breast Cancer. 2020; 21(1):57-73.e7. DOI: 10.1016/j.clbc.2020.07.013. View

16.

Cooper J, Giancotti F . Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019; 35(3):347-367. PMC: 6684107. DOI: 10.1016/j.ccell.2019.01.007. View

17.

Calin G, Ranzani G, Amadori D, Herlea V, Matei I, Barbanti-Brodano G . Somatic frameshift mutations in the Bloom syndrome BLM gene are frequent in sporadic gastric carcinomas with microsatellite mutator phenotype. BMC Genet. 2001; 2:14. PMC: 48142. DOI: 10.1186/1471-2156-2-14. View

18.

Li L, Gao M, Song B, Zhang H, Wang Y . Effects of RECQ1 helicase silencing on non-small cell lung cancer cells. Biomed Pharmacother. 2016; 83:1227-1232. DOI: 10.1016/j.biopha.2016.07.053. View

19.

Du X, Zhang C, Yin C, Wang W, Yan X, Xie D . High BLM Expression Predicts Poor Clinical Outcome and Contributes to Malignant Progression in Human Cholangiocarcinoma. Front Oncol. 2021; 11:633899. PMC: 8019910. DOI: 10.3389/fonc.2021.633899. View

20.

Wu J, Yu X, Zhu H, Chen P, Liu T, Yin R . RelB is a potential molecular biomarker for immunotherapy in human pan-cancer. Front Mol Biosci. 2023; 10:1178446. PMC: 10303125. DOI: 10.3389/fmolb.2023.1178446. View